News
Mannatech Declares Special 2020 Dividend
Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, announced that its Board of Directors declared a cash dividend
1347 Property Insurance Holdings, Inc. Reports Third Quarter 2020 Financial Results; Plans to Change Name to FG Financial Group, Inc.
1347 Property Insurance Holdings, Inc. (Nasdaq: PIH) (the “Company”), a holding company which is implementing business plans to operate as a diversified holding company of reinsurance and
1347 Property Insurance Holdings, Inc. Declares Cash Dividend on Its 8.00% Cumulative Preferred Stock, Series A
1347 Property Insurance Holdings, Inc. (Nasdaq: PIH) (the “Company”) announced today that it has declared a quarterly cash dividend on its 8.00% Cumulative Preferred Stock, Series A (the “Preferred
Genprex to Participate in Panel at Life Sciences Summit on November 17
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced
Fuel Tech Reports 2020 Third Quarter Financial Results
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MD
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced
Mannatech Reports Third Quarter End 2020 Financial Results
Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2020.
Fuel Tech Schedules Third Quarter 2020 Financial Results and Conference Call
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung Cancer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung Cancer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced
Dover Motorsports, Inc. Reports Results for the Third Quarter of 2020
Dover Motorsports, Inc. (NYSE: DVD) today reported results for the three months ended September 30, 2020.
As previously disclosed, the COVID-19 pandemic caused the postponement of the Company’s
Dover Motorsports, Inc. Declares Dividend
Dover Motorsports, Inc. (NYSE: DVD) Board of Directors today declared an annual cash dividend on both classes of common stock of $.07 per share. The dividend will be payable on December 10, 2020 to
Genprex Promotes Eric Chapdelaine to Vice President of Manufacturing
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced today
Dover Motorsports, Inc. Announces Third Quarter 2020 Earnings Release Date
Dover Motorsports, Inc. (NYSE: DVD) will report its earnings for the third quarter ended September 30, 2020 on the morning of Thursday, October 29, 2020. Commentary from the Company’s executive
No Brainer Club: Ex-Empfehlung mit +2.409% in 7 Monaten
Cardiff Oncology (WKN: A2P4GU) ist einer der diesjährigen Überflieger an der Nasdaq. Seit ihrem Jahrestief bei 0,70 USD steht für die Aktie eine gigantische Performance von +2.409% in nur sieben
Genprex to Present at Zooming with LD Micro on October 14, 2020
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced
Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today
Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split
Novus Therapeutics, Inc. (NASDAQ : NVUS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a reverse stock split of its
Bradley W. Johnson Appointed General Counsel of Fuel Tech
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
Fuel Tech Announces Listing Transfer to NASDAQ Capital Market® and 180 Day Extension to Regain Compliance With Minimum Bid Requirement
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
Genprex Names Seasoned IP Executive, Thomas C. Gallagher, as Senior Vice President of Intellectual Property and Licensing
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today
Fuel Tech Receives $2.6 Million Insurance Reimbursement
Fuel Tech, Inc. (NASDAQ:FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biotechnology company targeting the CD40L pathway to develop potential treatments for organ or cell-based transplant, autoimmune
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that after the conclusion of 4-years of
Novus Therapeutics Announces Acquisition of Anelixis Therapeutics
Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS) today announced it has completed the acquisition of Anelixis Therapeutics, Inc. (“Anelixis”), a privately held clinical stage biotechnology company